Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
RTOG-1106 trial: what clinicians have said so far
Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer
- NCT01507428 ↗
- Completed
- National Cancer Institute (NCI)
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on RTOG-1106 (stage III non-small cell lung cancer; tests a strategy, not a drug) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on RTOG-1106 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built | |
| 2 YouTube videos, typically up to 9 once built | |
| 1 podcast episode, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- Randomized Phase II Trial of Individualized Adaptive Radiotherapy Using During-Treatment FDG-PET/CT and Modern Technology in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Stage III Lung Non-Small Cell Cancer AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7; Stage IIIB Lung Non-Small Cell Cancer AJCC v7
- Interventions
- 18F-Fluoromisonidazole; Carboplatin; Computed Tomography; Computed Tomography; External Beam Radiation Therapy; Fludeoxyglucose F-18; Image-Guided Adaptive Radiation Therapy; Laboratory Biomarker Analysis; Paclitaxel; Positron Emission Tomography; Positron Emission Tomography
- Arms
- Arm I (standard chemoradiotherapy) · Active comparator
- Arm II (experimental chemoradiotherapy) · Experimental
- Enrollment
- 138
- Primary outcomes
- Percentage of Participants Alive Without Local-regional Progression [Local-regional Progression-free (LRPF) Survival] at Two Years (NRG)
- Relative Change in SUVpeak From the Baseline to the During-treatment Fludeoxyglucose F 18 (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) to LRPF With a 2-year Follow up. (ECOG-ACRIN)
- Sponsor
- National Cancer Institute (NCI) with NRG Oncology
- Start
- Feb 22, 2012
- Primary completion
- Aug 17, 2020
- Results posted
- Yes
- Registry record
- NCT01507428 · updated Apr 21, 2026
Publications
linked from the registry- Kong FS, Hu C, Pryma DA, Duan F, Matuszak M, Xiao Y, Ten Haken R, Siegel MJ, Hanna L, Curran WJ, Dunphy M, Gelblum D, Piert M, Jolly S, Robinson CG, Quon A, Loo BW, Srinivas S, Videtic GM, Faria SL, Ferguson C, Dunlap NE, Kundapur V, Paulus R, Siegel BA, Bradley JD, Machtay M. Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Stage III Non-Small Cell Lung Cancer. J Clin Oncol. 2024 Nov 20;42(33):3935-3946. doi: 10.1200/JCO.24.00022. Epub 2024 Oct 4. PubMed 39365957